127 related articles for article (PubMed ID: 18378952)
1. What is the best end point for hepatitis B treatment?
Lai CL; Yuen MF
Ann Intern Med; 2008 Apr; 148(7):560; author reply 560-1. PubMed ID: 18378952
[No Abstract] [Full Text] [Related]
2. When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?
Degertekin B; Lok AS
Ann Intern Med; 2007 Jul; 147(1):62-4. PubMed ID: 17606963
[No Abstract] [Full Text] [Related]
3. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.
Lai CL; Yuen MF
Ann Intern Med; 2007 Jul; 147(1):58-61. PubMed ID: 17606962
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus surface antigen mutants persist in chronic carriers receiving lamivudine therapy in Singapore.
Chen WN; Oon CJ; Lim GK
J Antimicrob Chemother; 2002 Jun; 49(6):1044-6. PubMed ID: 12039904
[No Abstract] [Full Text] [Related]
5. [Antiviral therapy in hepatitis B carriers undergoing immunosuppressive treatment or cytotoxic chemotherapy].
Yoon JH
Korean J Hepatol; 2005 Mar; 11(1):17-20. PubMed ID: 15788879
[No Abstract] [Full Text] [Related]
6. [Research advances in necessity of antiviral therapy for chronic hepatitis B virus carriers].
Long Q; Yao YQ; Yan CG
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):465-8. PubMed ID: 27465955
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis B in children and adolescents.
Paganelli M; Stephenne X; Sokal EM
J Hepatol; 2012 Oct; 57(4):885-96. PubMed ID: 22634122
[No Abstract] [Full Text] [Related]
8. Accuracy of a referral guideline for patients with chronic hepatitis B in primary care to select patients eligible for evaluation by a specialist.
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Gut; 2007 Jul; 56(7):1027-8. PubMed ID: 17566039
[No Abstract] [Full Text] [Related]
9. [Therapeutic and preventive activities of lamivudine on HBV re-activation in HBV carriers with immunodeficiency].
Liang XS; Wan MB; Chen JX; Li CZ; Song Y; Chen Y
Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):382-3. PubMed ID: 15918979
[No Abstract] [Full Text] [Related]
10. Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected and asymptomatic chronic hepatitis virus B carriers at Bangladesh.
Al-Mahtab M; Rahman S; Akbar SM; Khan SI; Uddin H; Karim F; Ahmed F
Viral Immunol; 2010 Jun; 23(3):335-8. PubMed ID: 20565297
[TBL] [Abstract][Full Text] [Related]
11. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection.
Habersetzer F; Moenne-Loccoz R; Meyer N; Schvoerer E; Simo-Noumbissie P; Dritsas S; Baumert TF; Doffoël M
Liver Int; 2015 Jan; 35(1):130-9. PubMed ID: 25145784
[TBL] [Abstract][Full Text] [Related]
12. Comments on the EASL practice guidelines for the management of chronic hepatitis B: controversies in interferon-based therapy.
Janssen HL; Buster EH
J Hepatol; 2009 Jul; 51(1):224-6. PubMed ID: 19410322
[No Abstract] [Full Text] [Related]
13. [Hepatitis B: the French point of view on EASL guidelines].
l'Association Française pour l'Etude du Foie
Gastroenterol Clin Biol; 2009; 33(6-7):535-8. PubMed ID: 19505784
[No Abstract] [Full Text] [Related]
14. Do guidelines preclude hepatitis B patients from receiving treatment?
Degertekin B; Lok AS
Hepatology; 2009 Feb; 49(2):700-1; author reply 701-2. PubMed ID: 19177583
[No Abstract] [Full Text] [Related]
15. Summary of BHIVA guidelines for HIV and hepatitis B or C co-infection.
Brook MG
J HIV Ther; 2003 Nov; 8(4):85-8. PubMed ID: 14671505
[TBL] [Abstract][Full Text] [Related]
16. An omission in the AASLD Practice Guidelines on Chronic Hepatitis B.
Jhaveri R; Murray N
Hepatology; 2007 Jul; 46(1):280; author reply 280. PubMed ID: 17596892
[No Abstract] [Full Text] [Related]
17. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
Cao Z; Liu Y; Ma L; Lu J; Jin Y; Ren S; He Z; Shen C; Chen X
Hepatology; 2017 Oct; 66(4):1058-1066. PubMed ID: 28407271
[TBL] [Abstract][Full Text] [Related]
18. AASLD Practice Guidelines on chronic hepatitis B and HBV infection in Italy.
Stroffolini T; Gaeta GB; Mele A
Hepatology; 2007 Aug; 46(2):608-9; author reply 609. PubMed ID: 17661422
[No Abstract] [Full Text] [Related]
19. EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy.
Papatheodoridis GV; Manolakopoulos S
J Hepatol; 2009 Jul; 51(1):226-7. PubMed ID: 19410321
[No Abstract] [Full Text] [Related]
20. [Treatment strategy for chronic hepatitis B in Japan].
Arase Y; Kumada H
Nihon Rinsho; 2011 May; 69 Suppl 4():475-9. PubMed ID: 22096964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
